Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has provided an update.
Recordati S.p.A. has announced an update on its share buyback program, which began on April 30, 2025, following a resolution from the Shareholders’ Meeting. The program, executed by UBS Europe SE, aims to purchase shares for stock option and performance share plans. Between September 22 and 26, 2025, Recordati purchased 196,951 ordinary shares, bringing its total holdings to 4,532,555 shares, equivalent to 2.167% of its share capital. This strategic move is part of Recordati’s efforts to enhance its incentive plans and align with its growth objectives.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR56.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, originating from a family-run pharmacy in Northern Italy in the 1920s. The company provides therapeutic options in both general and specialist medicine, as well as rare diseases, with a fully integrated approach from clinical development to production, marketing, and licensing of active ingredients and finished products. Recordati operates in about 150 countries across the EMEA, Americas, and APAC regions, employing over 4,580 people worldwide.
Average Trading Volume: 235,104
Technical Sentiment Signal: Buy
Current Market Cap: €10.56B
See more insights into REC stock on TipRanks’ Stock Analysis page.